RadioMedix, Curium win FDA clearance for Detectnet

By staff writers

September 8, 2020 -- Biotechnology firm RadioMedix and global nuclear medicine firm Curium have received U.S. Food and Drug Administration (FDA) clearance for their Detectnet PET diagnostic radiopharmaceutical copper-64 (Cu-64) DOTATATE.

Detectnet is indicated for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients, according to the vendors. Curium said it plans to immediately launch Detectnet. Doses will be available through various nuclear pharmacies or directly from Curium.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking